CN113181158A - 三酸甘油酯的固体组合物及其用途 - Google Patents

三酸甘油酯的固体组合物及其用途 Download PDF

Info

Publication number
CN113181158A
CN113181158A CN202110316004.0A CN202110316004A CN113181158A CN 113181158 A CN113181158 A CN 113181158A CN 202110316004 A CN202110316004 A CN 202110316004A CN 113181158 A CN113181158 A CN 113181158A
Authority
CN
China
Prior art keywords
less
solid
solid composition
triheptanoin
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110316004.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·克洛普
G·莫里斯
E·卡基斯
S·琼格勒斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ultragenyx Pharmaceutical Inc
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of CN113181158A publication Critical patent/CN113181158A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
CN202110316004.0A 2013-11-14 2014-11-14 三酸甘油酯的固体组合物及其用途 Pending CN113181158A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904369P 2013-11-14 2013-11-14
US61/904,369 2013-11-14
CN201480064471.7A CN105764497A (zh) 2013-11-14 2014-11-14 三酸甘油酯的固体组合物及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480064471.7A Division CN105764497A (zh) 2013-11-14 2014-11-14 三酸甘油酯的固体组合物及其用途

Publications (1)

Publication Number Publication Date
CN113181158A true CN113181158A (zh) 2021-07-30

Family

ID=53058066

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110316004.0A Pending CN113181158A (zh) 2013-11-14 2014-11-14 三酸甘油酯的固体组合物及其用途
CN201480064471.7A Pending CN105764497A (zh) 2013-11-14 2014-11-14 三酸甘油酯的固体组合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480064471.7A Pending CN105764497A (zh) 2013-11-14 2014-11-14 三酸甘油酯的固体组合物及其用途

Country Status (18)

Country Link
US (6) US20160243071A1 (enExample)
EP (2) EP3068383B1 (enExample)
JP (4) JP2017501972A (enExample)
KR (1) KR102291310B1 (enExample)
CN (2) CN113181158A (enExample)
AR (2) AR099353A1 (enExample)
AU (1) AU2014348470B2 (enExample)
CA (2) CA3197154A1 (enExample)
CL (1) CL2016001130A1 (enExample)
ES (1) ES2833294T3 (enExample)
IL (1) IL245588B (enExample)
MX (2) MX383005B (enExample)
MY (1) MY177028A (enExample)
PE (1) PE20161024A1 (enExample)
PH (1) PH12016500821A1 (enExample)
RU (1) RU2016123169A (enExample)
TW (1) TWI640327B (enExample)
WO (1) WO2015073816A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383005B (es) * 2013-11-14 2025-03-13 Ultragenyx Pharmaceutical Inc Composiciones solidas de trigliceridos y usos de estas.
US20190076383A1 (en) * 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
US12419852B2 (en) 2018-08-27 2025-09-23 Exerkine Corporation Method for treating lysosomal storage disease
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
CN113476408A (zh) * 2021-07-23 2021-10-08 兆科药业（广州）有限公司 一种苯丁酸甘油酯颗粒剂及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004099A1 (en) * 2004-07-02 2006-01-05 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
CN101919453A (zh) * 2010-08-16 2010-12-22 苏州市佳禾食品工业有限公司 中碳链脂肪酸粉末油脂及其制备方法
CN103079555A (zh) * 2010-06-14 2013-05-01 贝勒研究院 用于成人葡萄糖多聚体病（apbd）治疗的三庚酸甘油酯膳食
WO2013158616A1 (en) * 2012-04-16 2013-10-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treatment of medium-chain acyl-coa dehydrogenase deficiency

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2800610B2 (ja) * 1992-12-15 1998-09-21 不二製油株式会社 水中油型乳化物の製造法
JP3522843B2 (ja) * 1994-07-29 2004-04-26 昭和産業株式会社 リポ製剤
CA2212047C (en) * 1995-02-07 2010-11-16 Saul W. Brusilow Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
JPH08311480A (ja) * 1995-05-18 1996-11-26 D H Ee Kodo Seisei Chushutsu Gijutsu Kenkyu Kumiai 高純度トリアシルグリセロールからなる油脂の製造方法及び高度不飽和脂肪酸含有油脂組成物
NZ513329A (en) * 1999-02-05 2003-11-28 Baylor University Medical Ct Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
US8399515B2 (en) * 2003-05-20 2013-03-19 Baylor Research Institute Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements
US20050058673A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
US7141114B2 (en) * 2004-06-30 2006-11-28 Rec Silicon Inc Process for producing a crystalline silicon ingot
CA2599667C (en) * 2005-03-10 2014-12-16 3M Innovative Properties Company Antimicrobial compositions comprising esters of hydroxy carboxylic acids
CN101137359B (zh) * 2005-03-10 2011-01-12 3M创新有限公司 治疗耳感染的方法
JP2009525992A (ja) * 2006-02-10 2009-07-16 スポーツコム デンマーク アプス コーティングを施した錠剤、その製造方法、及び関連する使用
JP5296366B2 (ja) * 2007-10-29 2013-09-25 日清オイリオグループ株式会社 医薬品用持久力向上剤および持久力向上用医薬品
US8642012B2 (en) 2008-04-29 2014-02-04 Hyperion Therapeutics, Inc. Methods of treatment using ammonia-scavenging drugs
BR112014007357B1 (pt) 2011-09-30 2022-12-06 Immedica Pharma Ab Método para determinar o ajuste da dosagem de um fármaco de varredura de nitrogênio
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
CN104955450A (zh) 2012-12-13 2015-09-30 达拉斯贝勒研究院 用于治疗葡萄糖转运体1缺乏症的三庚酸甘油酯
MX383005B (es) * 2013-11-14 2025-03-13 Ultragenyx Pharmaceutical Inc Composiciones solidas de trigliceridos y usos de estas.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004099A1 (en) * 2004-07-02 2006-01-05 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
CN103079555A (zh) * 2010-06-14 2013-05-01 贝勒研究院 用于成人葡萄糖多聚体病（apbd）治疗的三庚酸甘油酯膳食
CN101919453A (zh) * 2010-08-16 2010-12-22 苏州市佳禾食品工业有限公司 中碳链脂肪酸粉末油脂及其制备方法
WO2013158616A1 (en) * 2012-04-16 2013-10-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treatment of medium-chain acyl-coa dehydrogenase deficiency

Also Published As

Publication number Publication date
TW201609189A (zh) 2016-03-16
US20160243071A1 (en) 2016-08-25
AR130666A2 (es) 2025-01-08
CA2929688A1 (en) 2015-05-21
CA3197154A1 (en) 2015-05-21
CN105764497A (zh) 2016-07-13
EP3068383A1 (en) 2016-09-21
EP3068383A4 (en) 2017-11-08
WO2015073816A1 (en) 2015-05-21
CA2929688C (en) 2023-06-13
JP2022107017A (ja) 2022-07-20
RU2016123169A (ru) 2017-12-19
MX2021001790A (es) 2021-04-19
US20250120936A1 (en) 2025-04-17
ES2833294T3 (es) 2021-06-14
AU2014348470B2 (en) 2020-01-30
EP3782610A1 (en) 2021-02-24
MX2016006329A (es) 2016-09-06
TWI640327B (zh) 2018-11-11
US20250120934A1 (en) 2025-04-17
KR20160084407A (ko) 2016-07-13
PH12016500821A1 (en) 2016-06-13
US20200069631A1 (en) 2020-03-05
AR099353A1 (es) 2016-07-20
PE20161024A1 (es) 2016-11-10
EP3068383B1 (en) 2020-09-16
IL245588A0 (en) 2016-06-30
US20230181513A1 (en) 2023-06-15
US20250120935A1 (en) 2025-04-17
JP2017501972A (ja) 2017-01-19
CL2016001130A1 (es) 2017-01-20
JP2020111585A (ja) 2020-07-27
MX383005B (es) 2025-03-13
AU2014348470A1 (en) 2016-05-26
IL245588B (en) 2021-08-31
MY177028A (en) 2020-09-02
KR102291310B1 (ko) 2021-08-23
JP2024129109A (ja) 2024-09-26

Similar Documents

Publication Publication Date Title
JP2024129109A (ja) トリグリセリドの固体組成物及びその使用
CA2683436C (en) Melatonin tablet and methods of preparation and use
CN101010067B (zh) 莫达非尼口腔冻干剂
CN101507704A (zh) 一种叶黄素固体分散体及其制备方法
WO2010143052A1 (en) Novel pharmaceutical compositions containing pregabalin
US20220142945A1 (en) Formulations including dihydrohonokiol
HK40056892A (en) Solid compositions of triglycerides and uses thereof
TW200914018A (en) Stable pharmaceutical composition comprising a hydrosoluble vinflunine salt
US11318090B1 (en) In situ gelling composition as a pH-selective and mucoadhesive sustained release drug delivery system
CN104640537A (zh) 用于口服剂型的低熔点丙酸衍生物粒子
BR112016010583B1 (pt) Composição, composição farmacêutica e uso das mesmas
WO2024080884A1 (en) Pharmaceutical compositions of tretinoin and methods of producing such compositions
CN105168155A (zh) 可直接压制的丙酸衍生物颗粒

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40056892

Country of ref document: HK